BiotechTube

zamtocabtagene autoleucel (MB-CART2019.1)

Phase 2Recruiting
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

B-Cell Neoplasm

Conditions

B-Cell Neoplasm

Trial Timeline

Aug 4, 2025 → Dec 31, 2029

NCT ID
NCT06508931

About zamtocabtagene autoleucel (MB-CART2019.1)

zamtocabtagene autoleucel (MB-CART2019.1) is a phase 2 stage product being developed by Thermo Fisher Scientific for B-Cell Neoplasm. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06508931. Target conditions include B-Cell Neoplasm.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06508931Phase 2Recruiting

Competing Products

20 competing products in B-Cell Neoplasm

See all competitors
ProductCompanyStageHype Score
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
CD19-CAR-T cellsAvalon GloboCarePhase 1
25
Sepantronium BromideCothera BiosciencePhase 2
44
rituximabCelltrionPhase 1
33
Valemetostat tosylateDaiichi SankyoPhase 2
52
ASP2802 + MA-20Astellas PharmaPhase 1
33
ONTAK (denileukin diftitox)EisaiPhase 2
52
TazemetostatEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
LOXO-338 + PirtobrutinibEli LillyPhase 1
33
PirtobrutinibEli LillyPre-clinical
23
Rituximab + GemcitabineEli LillyPhase 2
52
IbrutinibJohnson & JohnsonApproved
85
Ibrutinib 420 mg + Ibrutinib 560 mgJohnson & JohnsonApproved
85
ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapyJohnson & JohnsonPhase 2
52
VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + VincristineJohnson & JohnsonPhase 2
52
IbrutinibJohnson & JohnsonPre-clinical
23
SHR1459 tablet + Efavirenz tabletJiangsu Hengrui MedicinePhase 1
33

Other Products from Thermo Fisher Scientific

Tolvaptan + placeboPhase 3
76
BGP-15 100 mg QD + BGP-15 100 mg BID + Placebo BID + BGP-15 200 mg QD + BGP-15 200 mg BID + BGP-15 400 mg QDPhase 2
51
LR-ESHAP (lenalidomide 5 mg) + LR-ESHAP (lenalidomide 10 mg) + LR-ESHAP (lenalidomide 15 mg) + LR-ESHAP (lenalidomide 20 mg)Phase 1/2
40
ShA9 Topical Gel + Hydrocortisone Ointment + Clobetasol Ointment + Fluocinonide Ointment + Placebo (Vehicle) Topical GelPhase 1
32
Olokizumab + Omeprazole + Caffeine + Warfarin+ Vitamin K + MidazolamPhase 1
32